Description
This assay uses the Meso Scale Discovery® (MSD®) platform.
Consider this assay for comprehensive analysis of key biomarkers associated with neurological conditions. The Human MSD® Discovery Assay® Neurology 3-Plex Panel 1 (MSDN3) measures GFAP, NF-L, and Tau (total) levels.
Elevated levels of these biomarkers have been linked to various neurological conditions, including neuronal and brain injury (such as concussion), traumatic brain injury (TBI), neurodegeneration, and neuroinflammation. This panel is particularly valuable for studying conditions like stroke, multiple sclerosis (MS), and neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), motor neurone disease (MND), and amyotrophic lateral sclerosis (ALS). Elevated Tau levels are also observed in tauopathies such as frontotemporal dementia and progressive supranuclear palsy.
By measuring GFAP, NF-L, and Tau (total), this assay provides essential insights into diagnosing, monitoring disease progression, and evaluating treatment efficacy in neurological disorders. This panel offers a powerful tool for researchers and clinicians aiming to understand and address complex neurological conditions with precision and reliability.
The Human MSD® Discovery Assay® Neurology 3-Plex Panel 1 (MSDN3) is designed to deliver accurate results using the Meso Scale Discovery® (MSD®) platform, enabling simultaneous detection of multiple biomarkers from a single sample. This capability ensures efficient and comprehensive analysis, supporting advanced research and clinical applications in neurology.
This assay is optimized for analysis of Serum, Plasma, and CSF samples. If you have another sample type, please contact us prior to ordering this assay.
This assay has cross-reactivity with both mouse and rat samples. Consider this assay for preclinical neuro studies.
Click here for information on shipping biological samples for Discovery Assays
Published Research Featuring MSD® Neurology 3-Plex Panel 1:
- Kivisäkk, P., Carlyle, B. C., Sweeney, T., et al. (2023). Plasma biomarkers for diagnosis of Alzheimer’s disease and prediction of cognitive decline in individuals with mild cognitive impairment. Frontiers in Neurology, 14, 1069411.
- Spanos, M., Shachar, S., Sweeney, T., et al. (2022). Elevation of neural injury markers in patients with neurologic sequelae after hospitalization for SARS-CoV-2 infection. iScience, 25(8), 104833.